[6-K] Evaxion A/S Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate.” The company describes itself as a clinical-stage TechBio firm developing AI-Immunology powered vaccines. The press release, dated November 3, 2025, is included as Exhibit 99.1. This report is also incorporated by reference into Evaxion’s existing registration statements on Forms S-8, F-3, and F-1, making the 6-K part of those filings moving forward.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 3, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number		Description
99.1		Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: November 3, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion (EVAX) disclose in this Form 6-K?

Evaxion furnished a press release titled “Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate,” included as Exhibit 99.1.

When is the Evaxion press release dated?

The press release is dated November 3, 2025.

Which exhibit contains the press release in the 6-K?

The press release is furnished as Exhibit 99.1.

Does this 6-K integrate with other Evaxion filings?

Yes. It is incorporated by reference into registration statements on Form S-8 (333-255064), Form F-3 (333-265132), Form F-1 (333-266050), Form F-1 (333-276505), Form F-1 (333-279153), Form F-1 (333-283304), and Form F-3 (333-285778).

How does Evaxion describe its business in the filing?

Evaxion describes itself as a clinical-stage TechBio company developing AI-Immunology powered vaccines.

What is the main topic of the furnished press release?

The press release announces expansion of Evaxion’s R&D pipeline with a new AI-designed precision cancer vaccine candidate.